MADISON, Wis., March 16, 2021 /PRNewswire/ -- Gene therapy company ENDSULIN is looking for diabetic dogs to participate in a study to evaluate the effectiveness of a treatment that could reduce or even eliminate insulin injections.
The study could be a critical step in advancing a one-time diabetes treatment in both dogs and humans. The gene therapy is based on more than 25 years of research at the University of Wisconsin Hospitals and Clinics in Madison, and has proven efficacy in hundreds of small animals.
"We hope to free families who are caring for their diabetic pets around the clock," said Hans Sollinger, ENDSULIN founder. "Giving dogs and their families their independence back is a step in our mission to do the same for millions of people suffering with diabetes."
ENDSULIN covers the cost of the procedure, which takes about 30 minutes total and is administered by a certified veterinarian. After treatment, the ENDSULIN team will periodically monitor dogs' health to observe the long-term effects.
While this particular gene therapy is novel, dogs treated with gene therapies in Barcelona, Spain have been followed for up to 8 years, with no evidence of adverse events.
Ideal dogs are small breeds that have been recently diagnosed with diabetes. Families must be able to bring their pet to the ENDSULIN-designated clinic in Waunakee, WI, for the one-time treatment and five follow-up visits, and also provide follow-up information to the ENDSULIN research team.
ENDSULIN is reshaping the way we approach a cure for diabetes. They are working to free patients from daily injections and 24/7 management using the most cutting-edge gene therapy technology, developed from decades of research by noted diabetes leader Hans Sollinger, MD, PhD, Dr hc, at the University of Wisconsin Hospitals and Clinics. Their sole focus is to get a durable, one-time treatment to the millions of people who need it.